Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT05312801 is registered in ClinicalTrials.gov with Luminary Therapeutics as lead sponsor.

NCT NCT05312801
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05312801 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
LMY-920 for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
Lead sponsor
Luminary Therapeutics
Phase
Phase 1
Overall status
Recruiting
Start date
November 21, 2023
Completion date
September 2, 2025
Enrollment
20 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoma, non-hodgkin lymphoma, b-cell